Journal of psychoactive drugs
January 1, 2023
Aviad Hadar, Jonathan David, Nadav Shalit et al.
93 citations
Psychedelics were used to treat psychiatric conditions before their prohibition in the late 1960s. Over the past three decades, research interest in their therapeutic potential has revived, with expected FDA approvals for various conditions. This bibliometric analysis characterized the top-cited 100 articles in the field, which were cited between 82 and 668 times (median 125; mean 158). Fifty-four percent of these articles were published in the last decade (2010-2020). Network and author impact analysis identified key figures and collaboration networks. The UK, USA, Switzerland, Spain, and Brazil lead the field. The findings facilitate research evaluation, data-driven funding policies, and a practical map for researchers and clinicians.
Journal of psychopharmacology (Oxford, England)
April 21, 2025
Einat Karp Barnir, Zohar Rubinstein, Rany Abend et al.
7 citations
Among 343 adult survivors of a single large-scale terrorist attack at a festival, those who had consumed classic psychedelics during the attack reported significantly lower levels of anxiety and post-traumatic symptoms three weeks later, compared to those who took 3,4-methylenedioxymethamphetamine (MDMA) or no psychedelics. The protective effect against post-traumatic responses was stronger for participants who did not use other recreational substances alongside the psychedelics. These findings suggest that classic psychedelics may modulate the formation of enduring trauma memories and confer a protective effect against the development of post-traumatic stress and anxiety.
Journal of Psychedelic Studies
May 28, 2026
Lev Korchagin, Jonathan Fridman, Mario Mikulincer et al.
Among 422 recreational psychedelic users in Israel, 92% acknowledged the importance of testing substances for harm reduction, yet only 20% reported testing at least occasionally and only 4.3% always did so. 95% expressed readiness to use testing kits if provided free at the point of use. People who measured their substance dosages and those who obtained information from scientific research or online resources were more likely to test; those relying on friends for information tested less often. Employment status and sexual orientation were also associated with testing kit use. Legalizing and providing free testing kits at places of use may increase adoption of this harm reduction practice.